The indications were quite encouraging this week when the company published initial data from a phase 1b clinical trial of VERVE-102, a drug targeting heterozygous familial hypercholesterolemia (HeFH) ...

The studies will evaluate bempedoic acid alone and in combination with ezetimibe in pediatric patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial ...

Plasma exchange was first used to treat homozygous familial hypercholesterolemia (FH ... intermediate in heterozygous FH and fastest in subjects with normal LDL receptor function.

Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery ...

Adjunct to diet to reduce total-C, LDL-C and apo B in patients 10–16 years of age (≥1 year post-menarche) with heterozygous familial hypercholesterolemia if LDL-C remains ≥190mg/dL ...

The ENHANCE trial is a randomized study aimed at studying the effect of ezetimibe on top of simvastatin versus simvastatin on carotid intima–media thickness in 720 patients with heterozygous ...

The indications were quite encouraging this week when the company published initial data from a phase 1b clinical trial of VERVE-102, a drug targeting heterozygous familial hypercholesterolemia ...